Alexion Pharmaceuticals' Careers NewsEmployer Directory Featured Listing, Feeds and Subscriptions

The latest Alexion Pharmaceuticals careers news and job posts. Subscribe for daily updates to your inbox, mobile device and/or smartphone.

  Jobs Feed | Subscribe  

Position Summary The Senior Manager of Clinical Data Review in the Global Clinical Data Management (GCDM) department is responsible for the development of a clinical data review program and process to ensure the delivery of clinically-sound h...
Posted: June 18, 2019, 2:37 am
Position Summary The HR Shared Services Tier 1 Support Specialist plays a vital role serving as the primary contact for employees, managers, HR professionals as well as other internal and external business partners and third party entiti...
Posted: June 18, 2019, 2:37 am
Position Summary The Research Scientist III of Biomarkers & Bioanalytical is responsible for leading a team to provide biomarker project support for Alexion therapeutics at all stages of discovery and development. Responsibilities inclu...
Posted: June 17, 2019, 3:13 am
Position Summary The Clinical Development Scientist (CDS) provides input into the global clinical development plans and strategy for a therapeutic area. The job holder supports assigned clinical development physician(s) and the therapeu...
Posted: June 16, 2019, 3:09 am
Position Summary The Project Coordinator will be responsible for assisting the Strategy Programme Management and Data Sciences Department (DGB & SPPM) with the internal Alexion approval processes needed to begin and continue all projects...
Posted: June 14, 2019, 9:59 am

Viewing page 1 of 32|Next Page

  Newsfeed | Subscribe  

Like most of the stock market, the shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) have struggled in May, down nearly 10% so far. However, now could be an opportune time to roll the dice on ...
Posted: June 19, 2019, 12:00 am
Alexion Pharmaceuticals was up more than three percent midday but closed with a gain of 1.86 percent after Japanese regulators approved one of the firm's drugs to treat a rare blood disorder. Down ...
Posted: June 18, 2019, 2:15 pm
Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Alexion Pharmaceuticals' (NASDAQ:ALXN) ULTOMIRIS (ravulizumab), the first and only long-acting C5 complement inhibitor ...
Posted: June 18, 2019, 5:10 am
Alexion Pharmaceuticals ALXN announced positive, long-term data from the extension of the phase III study on Ultomiris and Soliris (eculizumab) in complement inhibitor-naïve, adult patients with ...
Posted: June 17, 2019, 5:03 pm
Alexion Pharmaceuticals announced the presentation of new data demonstrating that ULTOMIRIS (ravulizumab), the first and only long-acting C5 complement inhibitor administered every eight weeks, ...
Posted: June 17, 2019, 3:54 am

Viewing page 1 of 3|Next Page